/
BEAT
$0.65-$0.02 (-3.27%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$37.5M
56M shares
52-week range
$0.54 – $4.00
3% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
5.57%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-4.04
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $399.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $149.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $250.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 62.7% | — | — | — | — | — | — | — |
| R&D | $11.2M | $41.0K | $133.0K | $255.0K | $5.7M | $6.8M | $11.1M | $13.4M |
| Operating income | $84.0M | −$294.0K | −$788.0K | −$2.3M | −$13.0M | −$15.3M | −$19.9M | −$21.1M |
| EBITDA | $92.0M | $0 | $0 | −$2.3M | $69.0K | $675.0K | −$19.4M | −$21.0M |
| Net income | $42.8M | −$536.0K | −$1.1M | −$4.4M | −$13.0M | −$14.6M | −$19.4M | −$21.0M |
| Net margin | 10.7% | — | — | — | — | — | — | — |
| EPS (diluted) | 1.20 | -0.10 | -0.14 | -0.56 | -1.59 | -0.72 | -0.73 | -0.62 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $976500 | $-0.36 | $-0.39–$-0.32 | 2 |
| 2027 | $6M | $-0.28 | $-0.29–$-0.26 | 2 |
| 2028 | $21M | $-0.12 | $-0.20–$-0.03 | 2 |
| 2029 | $71M | $0.35 | $0.12–$0.54 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.10
Price
$0.65
Implied downside
-84%
Peer comparison
Heartbeam, Inc. Common Stock
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
www.heartbeam.com- Employees
- 17
- IPO / List date
- Nov 11, 2021
- HQ
- SANTA CLARA, CA
Held by traders on TradeandTell
No one on the platform currently holds BEAT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BEAT as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2005-08-18 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded BEAT yet.
